

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

CD28

RRID:AB_396068

Type: Antibody

Proper Citation

BD Biosciences Cat# 555725, RRID:AB_396068

Antibody Information

URL: http://antibodyregistry.org/AB_396068

Proper Citation: BD Biosciences Cat# 555725, RRID:AB_396068

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Bio, Flow cytometry

Antibody Name: CD28

Description: This monoclonal targets CD28

Target Organism: human

Antibody ID: AB_396068

Vendor: BD Biosciences

Catalog Number: 555725

Record Creation Time: 20250820T035925+0000

Record Last Update: 20250820T174408+0000

Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community. Contact(s): [Jing Chen](#), [Mark Atkinson](#), [Todd Brusko](#), [Clayton Mathews](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 63 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Castro RC, et al. (2026) Extracellular Vesicles Favor Early Peripheral Immunosenescence Through Modulation of the Senescence-Associated Secretory Phenotype in HIV Infection. *Aging cell*, 25(1), e70320.

Sun Y, et al. (2025) TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids. *Cancer immunology research*, 13(2), 210.

Carré A, et al. (2025) Interferon- γ promotes HLA-B-restricted presentation of conventional and alternative antigens in human pancreatic γ -cells. *Nature communications*, 16(1), 765.

Luo C, et al. (2025) Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. *Immunity*, 58(3), 745.

Loyal L, et al. (2025) Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly. *Cell reports*, 44(2), 115314.

Stampfer SD, et al. (2025) Mpox-specific cellular and humoral immunity in mpox survivors living with HIV. *Cell reports*, 44(11), 116501.

Zhang QS, et al. (2025) SHMT2 regulates CD8⁺ T cell senescence via the reactive oxygen species axis in HIV-1 infected patients on antiretroviral therapy. *EBioMedicine*, 112, 105533.

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. *Cell reports. Medicine*, 6(3), 101975.

Bone B, et al. (2025) Distinct viral reservoirs and immune signatures in individuals on long-term antiretroviral therapy with perinatally acquired HIV-1. *Cell reports. Medicine*, 6(6), 102150.

Harre P, et al. (2025) Dietary ω -3 polyunsaturated fatty acids (PUFAs) reduce cholesterol-driven non-small cell lung cancer (NSCLC) progression in mouse models of disease. *Communications medicine*, 5(1), 432.

Nesamari R, et al. (2024) Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant. *Cell host & microbe*, 32(2), 162.

Fert A, et al. (2024) Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies. *iScience*, 27(9), 110670.

Zhou S, et al. (2024) CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. *Cell reports. Medicine*, 5(12), 101844.

Vanhaver C, et al. (2024) Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype. *Life science alliance*, 7(1).

Benede N, et al. (2024) Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivity. *iScience*, 27(1), 108728.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. *Cell reports. Medicine*, 5(3), 101469.

Ma Y, et al. (2024) Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma. *Cell reports. Medicine*, 5(2), 101414.

Hirsch T, et al. (2024) IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression. *Cell reports*, 43(7), 114401.

Moore SC, et al. (2023) Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. *Med (New York, N.Y.)*, 4(3), 191.